Regeneron Pharmaceuticals, Inc. REGN obtained positive opinion for its pipeline candidate linvoseltamab from the European ...

Pharmaceuticals announced that the European Medicines Agency’s, EMA, Committee for Medicinal Products for Human Use, CHMP, has ...

Regeneron on Friday said the recommendation covers adults with adults with relapsed and refractory multiple myeloma who have received at least three prior therapies, including a proteasome inhibitor, ...

While Regeneron doesn’t make vaccines specifically, its monoclonal antibody therapy provides a "passive vaccine" effect, temporarily protecting against infections. Dupixent Could Gain 30% More U ...

(RTTNews) - Regeneron Pharmaceuticals (REGN ... an immunomodulatory agent and an anti-CD38 monoclonal antibody, and have demonstrated disease progression on the last therapy.

Regeneron Pharmaceuticals (NASDAQ:REGN) said the European Medicines Agency’s Committee for Medicinal Products for Human Use ...

Indeed, Regeneron believes that the success with Ebola could potentially have ushered in “a new era in which monoclonal antibodies could be used to fight viral diseases and global pandemics.” ...

A gene therapy from Regeneron Pharmaceuticals Inc. improved hearing in nearly all deaf children in a clinical trial, results that could allow the company to seek regulatory approval for the one ...

In Regeneron Pharmaceuticals Inc.’s phase I/II Chord study of 12 children with genetic hearing loss tied to the variants of the otoferlin gene, 10 out of 11 have showed notable improvements in their ...

and anti-CD38 monoclonal antibody, and Regeneron is planning to file linvoseltamab in the same setting. Dosing could be another point of difference for the new drug. Elrexfio has a slight edge ...

KPL-387 is an independently developed monoclonal antibody that binds human interleukin-1 receptor ... ARCALYST was discovered by Regeneron Pharmaceuticals, Inc. (Regeneron) and is approved by the U.S.